Scancell and Cancer Research Technology announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7
NOTTINGHAM, England | August 10, 2010 | Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd (‘CRT’) – Cancer Research UK’s commercialisation and development arm – today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55. The antibody was discovered and originally developed at the University of Nottingham with support from Cancer Research UK and has previously been evaluated in clinical trials for osteosarcoma. The agreement will give Scancell a worldwide licence to use 105AD7 for the development of new ImmunoBody® vaccines for any immunotherapy indication.
The licence will be restricted to the use of the antibody as a framework for future ImmunoBody® vaccines.
Scancell’s current ImmunoBody® vaccines, such as SCIB1, its vaccine currently in Phase I clinical trials for the treatment of melanoma, use a deimmunised* antibody as the framework. 105AD7 will allow Scancell to use a fully human framework for the development of future ImmunoBody® vaccines.
Under the terms of the agreement, Scancell will make an upfront payment to CRT in addition to development milestone payments, and royalty payments on future sales. Scancell will exclusively fund the development work, and have sub-licensing rights on agreed terms.
Professor Lindy Durrant, Chief Executive Officer of Scancell, commented:
“I am pleased that we have secured this important agreement with Cancer Research Technology. By utilising antibody 105AD7, Scancell will be able to further enhance the clinical utility and safety of Scancell’s ImmunoBody® platform both in cancer and other immunotherapy indications.”
Dr Phil L’Huillier, Cancer Research Technology’s director of business management, said:
“Through this deal with Scancell we are able to take forward this antibody arising from research from our world-class scientists into commercial development to potentially make new vaccines to treat a range of diseases.”
A copy of this announcement is available for download on the Company’s website at http://www.scancell.co.uk/
*Deimmunization is a technology for location and removal of T-cell epitopes through the combined use of immunological and molecular biology techniques to reduce the immunogenicity of an antibody.
SOURCE: Scancell Holdings Plc
Post Views: 34
Scancell and Cancer Research Technology announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7
NOTTINGHAM, England | August 10, 2010 | Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd (‘CRT’) – Cancer Research UK’s commercialisation and development arm – today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55. The antibody was discovered and originally developed at the University of Nottingham with support from Cancer Research UK and has previously been evaluated in clinical trials for osteosarcoma. The agreement will give Scancell a worldwide licence to use 105AD7 for the development of new ImmunoBody® vaccines for any immunotherapy indication.
The licence will be restricted to the use of the antibody as a framework for future ImmunoBody® vaccines.
Scancell’s current ImmunoBody® vaccines, such as SCIB1, its vaccine currently in Phase I clinical trials for the treatment of melanoma, use a deimmunised* antibody as the framework. 105AD7 will allow Scancell to use a fully human framework for the development of future ImmunoBody® vaccines.
Under the terms of the agreement, Scancell will make an upfront payment to CRT in addition to development milestone payments, and royalty payments on future sales. Scancell will exclusively fund the development work, and have sub-licensing rights on agreed terms.
Professor Lindy Durrant, Chief Executive Officer of Scancell, commented:
“I am pleased that we have secured this important agreement with Cancer Research Technology. By utilising antibody 105AD7, Scancell will be able to further enhance the clinical utility and safety of Scancell’s ImmunoBody® platform both in cancer and other immunotherapy indications.”
Dr Phil L’Huillier, Cancer Research Technology’s director of business management, said:
“Through this deal with Scancell we are able to take forward this antibody arising from research from our world-class scientists into commercial development to potentially make new vaccines to treat a range of diseases.”
A copy of this announcement is available for download on the Company’s website at http://www.scancell.co.uk/
*Deimmunization is a technology for location and removal of T-cell epitopes through the combined use of immunological and molecular biology techniques to reduce the immunogenicity of an antibody.
SOURCE: Scancell Holdings Plc
Post Views: 34
